Table 4 KEGG and PANTHER pathway analyses of the validated targets of CTD-2547G23.4
Category | Term | Count | P value |
|---|---|---|---|
KEGG_PATHWAY | hsa04720: long-term potentiation | 7 | 6.32E−04 |
KEGG_PATHWAY | hsa04912: GnRH signalling pathway | 7 | 4.18E−03 |
KEGG_PATHWAY | hsa04916: melanogenesis | 6 | 1.92E−02 |
KEGG_PATHWAY | hsa04020: calcium signalling pathway | 8 | 2.00E−02 |
KEGG_PATHWAY | hsa04114: Oocyte meiosis | 6 | 2.88E−02 |
KEGG_PATHWAY | hsa04080: neuroactive ligand-receptor interaction | 9 | 4.68E−02 |
KEGG_PATHWAY | hsa04742: taste transduction | 4 | 4.78E−02 |
PANTHER_PATHWAY | P00026: heterotrimeric G-protein signalling pathway: Gi alpha and Gs alpha-mediated pathway | 10 | 4.43E−03 |
PANTHER_PATHWAY | P00049: parkinson disease | 7 | 1.15E−02 |
PANTHER_PATHWAY | P00027: heterotrimeric G-protein signalling pathway: Gq alpha and Go alpha-mediated pathway | 8 | 1.98E−02 |
PANTHER_PATHWAY | P00037: Ionotropic glutamate receptor pathway | 5 | 2.03E−02 |
PANTHER_PATHWAY | P00041: metabotropic glutamate receptor group I pathway | 4 | 4.10E−02 |
PANTHER_PATHWAY | P00057: Wnt signalling pathway | 12 | 4.25E−02 |